Sign In  |  Register  |  About Los Altos  |  Contact Us

Los Altos, CA
September 01, 2020 1:26pm
7-Day Forecast | Traffic

  • Search Hotels in Los Altos

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Cybin Inc (NY: CYBN )

10.78 -0.62 (-5.44%)
Official Closing Price Updated: 8:00 PM EST, Nov 8, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Cybin Inc

< Previous 1 2
...
13 14 15 16 17 18 19 20 21
...
38 39 Next >
Cybin to Participate in the Jefferies London Healthcare Conference and Upcoming Investor Events
From Cybin Inc.
Via Business Wire
Compass Pathways, Small Pharma Among Top Psychedelic Movers Of Today
GAINERS: GH Research (NASDAQ:GHRS) shares closed up 3.90% at $10.39 LOSERS: 
Via Benzinga
PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Exec to Present at Neuropsychiatric & Psychedelics Drug Development Summit
Via Investor Brand Network
Cybin Announces Scientific Presentation at the 5th Annual Neuropsychiatric & Psychedelics Drug Development Summit
From Cybin Inc.
Via Business Wire
15 Global Psychedelics Executives To Keep An Eye On In 2022
As the global psychedelics industry booms, with companies going public, major financings being announced, and celebrities and big investors getting on board, Benzinga has decided to put together a list... 
Via Benzinga
October Recap: Major Psychedelic Drug Stocks Declined 9.9%
In total, thePsychedelic Drug Stock Index went down 9.9% in September and is now down 64.7% YTD. 
Via Talk Markets
Revive Therapeutics, Small Pharma Among Top Psychedelic Movers Of Today
GAINERS: Seelos Therapeutics (NASDAQ:SEEL) shares closed up 3.00% at $0.87 
Via Benzinga
PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) EMBARK Program Graduates Class of Facilitators
Via Investor Brand Network
Cybin’s EMBARK Program Announces Graduation of Facilitators
From Cybin Inc.
Via Business Wire
Psychedelic Stock Gainers And Losers From October 26, 2022
GAINERS: Revive Therapeutics (OTC:RVVTF) shares closed up 5.39% at $0.18 
Via Benzinga
Psychedelic Stock Gainers And Losers From October 25, 2022
GAINERS: Compass Pathways (NASDAQ:CMPS) shares closed up 6.24% at $10.39 
Via Benzinga
Cannabis Category Performances Ranged From +14.4% To -4.6% This Past Week
The 5 categories in the cannabis sector perform quite differently week to week. Below is a summary of how each category performed last week, in descending order and since the end of September and since... 
Via Talk Markets
Major Psychedelic Stock Downward Trend Continues
The 8 constituents of our Psychedelic Drug Stocks Index continue to collectively show poor performance, down 4.6% more last week and now down 45.5% since the end of August. 
Via Talk Markets
Allied, Small Pharma Among Top Psychedelic Movers Of Today
GAINERS: Allied (OTC:ALID) shares closed up 10.21% at $0.53 
Via Benzinga
Psychedelic Stock Gainers And Losers From October 18, 2022
GAINERS: Small Pharma (OTC:DMTTF) shares closed up 15.76% at $0.14 
Via Benzinga
Psychedelic Stock Gainers And Losers From October 17, 2022
GAINERS: Biomind Labs (OTC:BMNDF) shares closed up 38.18% at $1.52 
Via Benzinga
PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Continues Focus to Create the Best Psychedelic Therapies for Patients
Via Investor Brand Network
Small Pharma, Cybin Among Top Psychedelic Movers Of Today
GAINERS: Small Pharma (OTC:DMTTF) shares closed up 9.12% at $0.12 
Via Benzinga
Psychedelic Stock Gainers And Losers From October 12, 2022
GAINERS: Allied (OTC:ALID) shares closed up 48.05% at $0.48 
Via Benzinga
Numinus Wellness, Small Pharma Among Top Psychedelic Movers Of Today
GAINERS: Small Pharma (OTC:DMTTF) shares closed up 7.61% at $0.12 
Via Benzinga
TinyGemsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN), The Chopra Foundation Note World Mental Health Day
Via Investor Brand Network
Psychedelic Drugs Prove Their Worth In Clinical Trials
Novel psychedelic drugs have continuously proven their worth in clinical trials. Just recently, one company revealed that it was in the process of finalizing its Phase 1 first-in-human clinical trial... 
Via PressReach
Psychedelic Stock Gainers And Losers From October 10, 2022
GAINERS: Cybin (AMEX:CYBN) shares closed up 5.51% at $0.63 LOSERS: 
Via Benzinga
Cybin & The Chopra Foundation Recognize World Mental Health Day
From Cybin Inc.
Via Business Wire
Psychedelic Drug Stocks Index Up Slightly This Week
There are 8 stocks in the munKNEE Psychedelic Drug Stocks Index and this article reveals how its constituents performed this week, in descending order, since the end of August and YTD. 
Via Talk Markets
Psychedelic Stock Gainers And Losers From October 6, 2022
GAINERS: Revive Therapeutics (OTC:RVVTF) shares closed up 45.41% at $0.22 
Via Benzinga
PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) ‘Focused on Adding Targeted IP’
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
Cybin Provides Update on its Intellectual Property Portfolio
From Cybin Inc.
Via Business Wire
Colorado to Vote on Legalizing Psychoactives in November
Voters in Colorado will have a say in the legalization of psychedelic drugs this November as an initiative to legalize psilocybin mushrooms and other naturally occurring psychedelics appears on the... 
Via PressReach
Topics Supply Chain
Exposures Supply Chain
Allied, GH Research Among Top Psychedelic Movers Of Today
GAINERS: Allied (OTC:ALID) shares closed up 31.58% at $0.60 
Via Benzinga
< Previous 1 2
...
13 14 15 16 17 18 19 20 21
...
38 39 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 LosAltos.com & California Media Partners, LLC. All rights reserved.